# OnCo record nct07244705 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07244705/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07244705", "NCT07244705" ;
  schema:name "A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC"@en ;
  schema:description "A phase 1/2 trial of ABT-301, Tislelizumab, Bevacizumab in colorectal cancer, run by Anbogen Therapeutics, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07244705/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07244705> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-11" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/abt-301/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/anbogen-therapeutics/> .